Thursday, August 13, 2015

Cara Pharmaceuticals - All Time High

Cara Pharmaceuticals (CARA) is the Barchart Chart of the Day.  The biopharmaceutical company has a Trend Spotter buy signal, a Weighted Alpha of 144.40+, and gained 116.75% in the last year.


The Chart of the Day belongs to Cara Pharmaceuticals (CARA).  I found the Biopharmceutical stock by using Barchart to sort today's All Time High list for the stocks with the highest Weighted Alpha then sorted again for the stocks with  technical buy signals of 80% or better.  Next I used the Flipchart feature to review the charts.  Since the Trend Spotter signaled a buy on 6/13 the stock gained 103.33%.

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.

The status of Barchart's Opinion trading systems are listed below.  Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates.  The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

  • 88% Barchart technical buy signals
  • 114.40+ Weighted Alpha
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 11 new highs and up 62.96% in the last month
  • Relative Strength Index 69.37%
  • Barchart computes a technical support level at 20.69
  • Recently traded at 22.00 with a 50 day moving average of 15.10
Fundamental factors:
  • Market Cap $502.26
  • Revenue expected to increase 15.50% this year and another 47.70% next year
  • Earnings estimated to decrease 21.20% this year and an additional 29.10% next year
  • Despite that decrease in earnings Wall Street analysts issued 3 strong buy and 4 buy recommendations on the stock
The 50 Day Moving Average vs Price has been an effective technical trading strategy for this stock.


No comments:

Post a Comment